AI assistant
ARIX BIOSCIENCE PLC Director's Dealing 2023
4968_dirs_2023-05-02_0875af04-4b2a-45ce-a7a7-4c27e479dcd0.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 1654Y
Arix Bioscience Plc
02 May 2023
Arix Bioscience plc
("Company")
PDMR notifications & Director Shareholdings
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Arix Bioscience Plc has been notified of the following transactions relating to the below named PDMRs and their respective interests in the ordinary share capital of the Company ('Shares'):
Peregrine Moncreiffe, Non-Executive Director and Chairman of the Board purchased 75,000 Ordinary shares of 0.001 pence each in the Company ("Shares") on 27 April 2023 at a price of 102.5 pence per share and purchased a further 85,000 Shares in the Company on 28 April 2023 at a price of 104.8 pence per share.
Debra Barker, Non-Executive Director and Senior Independent Director purchased 24,000 Shares in the Company on 27 April 2023 at a price of 103 pence per share.
Robert Lyne, Chief Executive Officer purchased 24,330 Shares in the Company on 27 April 2023 at a price of 102.75 pence per share.
In a separate transaction, Robert Lyne exercised vested options over 203,764 shares ("Option Shares") on 27 April 2023 pursuant to a nil cost share award granted on 30 June 2020. 96,107 of the Shares were sold on 27 April 2023 at a sale price of 101.5 pence per share to satisfy the resultant income tax and National Insurance liability.
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further detail on the respective transactions.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Peregrine Moncreiffe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director and Chair of the Board | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Arix Bioscience plc | |||
| b) | LEI | 213800OVT3AHQCXNIX43 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Arix Bioscience plc Ordinary shares of 0.001 pence each | |||
| Identification code | GB00BD045071 | ||||
| b) | Nature of the transaction | Share purchase | |||
| c) | Price(s) and volume(s) | Price(s)£ | Volume(s) | ||
| 27 April 2023 28 April 2023 |
1.025 1.048 |
75,000 85,000 |
|||
| d) | Aggregated information | ||||
| - Aggregated volume | 160,000 | ||||
| - Price | £165,962.50 | ||||
| e) | Date of the transaction | 27 April 2023 28 April 2023 | |||
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Robert Lyne | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Executive Officer | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Arix Bioscience plc | |||
| b) | LEI | 213800OVT3AHQCXNIX43 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Arix Bioscience plc Ordinary shares of 0.001 pence each | |||
| Identification code | GB00BD045071 | ||||
| b) | Nature of the transaction | Share Purchase | |||
| c) | Price(s) and volume(s) | Price(s)£ | Volume(s) | ||
| £1.0275 | 24,330 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A (Single Transaction) | ||||
| - Price | £24,999.08 | ||||
| e) | Date of the transaction | 27 April 2023 | |||
| f) | Place of the transaction | London Stock Exchange |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Robert Lyne | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Executive Officer | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Arix Bioscience plc | |||
| b) | LEI | 213800OVT3AHQCXNIX43 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Arix Bioscience plc Ordinary shares of 0.001 pence each | |||
| Identification code | GB00BD045071 | ||||
| b) | Nature of the transaction | Vesting of awards under the Company's Executive Incentive Plan ("EIP") 2020 and sale of shares to cover associated tax liabilities | |||
| c) | Price(s) and volume(s) | Price(s)£ | Volume(s) | ||
| 1.) Acquisition £nil per share 2.) Disposal £1.015 |
203,764 96,107 |
||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A (Single Transaction) | ||||
| - Price | £97,548.61 | ||||
| e) | Date of the transaction | 27 April 2023 | |||
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Debra Barker | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Arix Bioscience plc | |||
| b) | LEI | 213800OVT3AHQCXNIX43 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Arix Bioscience plc Ordinary shares of 0.001 pence each | |||
| Identification code | GB00BD045071 | ||||
| b) | Nature of the transaction | Share purchase | |||
| c) | Price(s) and volume(s) | Price(s) £ £1.03.00 |
Volume(s) 24,000 |
||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A (single transaction) | ||||
| - Price | £24,720.00 | ||||
| e) | Date of the transaction | 27 April 2023 | |||
| f) | Place of the transaction | London Stock Exchange |
Ends.
For further information please contact:
Kin Company Secretarial Limited, Company Secretary
+44 20 8819 6486
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHZLLFBXELEBBF